Mergers & Acquisitions ·
Mentari Therapeutics completes merger with InMed and raises $490 million in PIPE financing
INMInMed Pharmaceuticals Inc.
On November 6, 2026, Mentari Therapeutics (formerly InMed Pharmaceuticals) consummated a business combination with InMed. The transaction included a $490 million private investment in public equity (PIPE), which funded the conversion of Mentari's convertible notes and provided capital for the combined entity. Following the merger, Mentari shareholders own approximately 99% of the new company, while former InMed shareholders hold about 1%. The deal involved a reverse stock split, redomestication to Nevada, and the issuance of contingent value rights (CVRs) to InMed holders tied to the disposition of legacy cannabinoid programs. Mentari Therapeutics operates in the biopharmaceutical industry.